Nxera Pharma Stock Forecast

Stock Price Forecast

According to 8 analysts polled by S&P Global, Nxera Pharma stock has a consensus rating of "Buy" and an average price target of ¥2,015. The average 1-year stock price forecast is 68.76% higher than the current stock price, while the lowest is ¥1,000 (-16.25%) and the highest is ¥4,500 (+276.88%).

Price Target: ¥2,015 (+68.76%)

Analyst Consensus: Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	¥1,000	¥2,015	¥1,800	¥4,500
Change	-16.25%	+68.76%	+50.75%	+276.88%

Analyst Ratings

The average analyst rating for Nxera Pharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart

Rating	Apr '26	May '26	Jun '26	Jul '26	Aug '26	Sep '26
Strong Buy	5	5	5	5	5	5
Buy	1	1	1	1	1	1
Hold	2	2	2	2	2	2
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	8	8	8	8	8	8

Financial Forecast

Revenue This Year

41.03B

from 29.62B

38.54%

from 29.62B

Revenue Next Year

41.78B

from 41.03B

1.82%

from 41.03B

EPS This Year

n/a

from -

EPS Next Year

n/a

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	17.71B	15.57B	12.77B	28.84B	29.62B	41.03B
Revenue Growth	100.32%	-12.10%	-18.00%	125.87%	2.71%	38.54%
Gross Profit	16.78B	14.64B	9.66B	21.22B	21.42B	34.72B
Gross Margin	94.73%	94.05%	75.70%	73.59%	72.32%	84.63%
Operating Income	6.91B	2.81B	-10.40B	-6.62B	-8.27B	7.23B
Net Income	1.02B	382.00M	-7.19B	-4.84B	-12.53B	4.65B
Free Cash Flow	8.54B	-1.37B	-11.53B	-9.25B	-2.53B	7.70B
No. Analysts	-	-	-	-	-	7

Financial currency is JPY.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	46.4B
Avg	41.0B
Low	36.5B

Revenue Growth

Chart

Revenue Growth	2026	2027	2028
High	56.7%
Avg	38.5%
Low	23.2%

EPS Forecast

Chart

EPS	2026	2027	2028
High	-
Avg	-
Low	-

EPS Growth

Chart

EPS Growth	2027	2028
High	-
Avg	-
Low	-